1. Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial. (October 2020) Authors: Schett, Georg; Bainbridge, Chris; Berkowitz, Mario; Davy, Katherine; Fernandes, Sofia; Griep, Eduard; Harrison, Stephen; Gupta, Anubha; Lloyd-Hughes, James; Roberts, Alexandra; Layton, Mark; Nowak, Nonna Anna; Patel, Jatin; Rech, Jürgen; Smith, Julia E; Watts, Sarah; Tak, Paul P Journal: Lancet Issue: Volume 2:Number 10(2020) Page Start: e623 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. MRI of the joint and evaluation of the granulocyte–macrophage colony-stimulating factor–CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study. (November 2020) Authors: Genovese, Mark C; Berkowitz, Mario; Conaghan, Philip G; Peterfy, Charles; Davy, Katherine; Fisheleva, Elena; Gupta, Anubha; Inman, David; Janiczek, Robert; Layton, Mark; Mitchell, Nina; Patel, Jatin; Roberts, Alexandra; Saurigny, Didier; Smith, Julia E; Williamson, Russell; Tak, Paul P Journal: Lancet Issue: Volume 2:Number 11(2020) Page Start: e666 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Issue 1 (12th February 2020) Authors: Bhandari, Sunil; Kalra, Philip A; Berkowitz, Mario; Belo, Diogo; Thomsen, Lars L; Wolf, Myles Journal: Nephrology dialysis transplantation Issue: Volume 36:Issue 1(2021) Page Start: 111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗